⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VTGN News
Vistagen Therapeutics, Inc. Common Stock
Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeutics, Inc. (VTGN) Shareholders to Inquire about Securities Investigation
accessnewswire.com
VTGN
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Shareholders to Connect
accessnewswire.com
VTGN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Shareholders to Reach Out
accessnewswire.com
VTGN
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
businesswire.com
VTGN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Shareholders to Learn More About the Investigation
accessnewswire.com
VTGN
Form 8-K
sec.gov
VTGN
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
businesswire.com
VTGN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Investors to Learn More About the Investigation
accessnewswire.com
VTGN
Form 8-K
sec.gov
VTGN
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
businesswire.com
VTGN